Jan 14, 2020 / 04:30PM GMT
Cory William Kasimov - JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst
All right. Good morning, everyone. My name is Cory Kasimov. I'm the senior large-cap biotech analyst at JPMorgan, and it's my pleasure to introduce our next company, which is Amgen. Here to present is their company's Chairman and CEO, Bob Bradway. And please note that following Bob's presentation, there is a breakout across the hall in the Borgia room.
With that, I turn it over to Bob.
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Okay. Thank you, Cory, and good morning, everyone. Thank you for being here. Heading into 2020, we're feeling confident at Amgen and excited about accepting the challenges of the future. Speaking of the future, my remarks this morning are qualified by the elements of the safe harbor statement.
As we think about 2019, we feel we made significant progress on executing our strategy for long-term growth. And in each of our therapeutic areas, we have growth drivers that will be based on growth in volume
Amgen Inc at JPMorgan Healthcare Conference Transcript
Jan 14, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers